Skunk River Review Fall 2001, vol 13

https://openspace.dmacc.edu/skunkriver/1022/thumbnail.jp

Colorado Ultraviolet Transit Experiment: a dedicated CubeSat mission to study exoplanetary mass loss and magnetic fields

The Colorado Ultraviolet Transit Experiment (CUTE) is a near-UV (2550 to 3300  Å) 6U CubeSat mission designed to monitor transiting hot Jupiters to quantify their atmospheric mass loss and magnetic fields. CUTE will probe both atomic (Mg and Fe) and molecular (OH) lines for evidence of enhanced transit absorption, and to search for evidence of early ingress due to bow shocks ahead of the planet’s orbital motion. As a dedicated mission, CUTE will observe ≳100 spectroscopic transits of hot Jupiters over a nominal 7-month mission. This represents the equivalent of <700 orbits of the only other instrument capable of these measurements, the Hubble Space Telescope. CUTE efficiently utilizes the available CubeSat volume by means of an innovative optical design to achieve a projected effective area of ∼28  cm^2, low instrumental background, and a spectral resolving power of R∼3000 over the primary science bandpass. These performance characteristics enable CUTE to discern transit depths between 0.1% and 1% in individual spectral absorption lines. We present the CUTE optical and mechanical design, a summary of the science motivation and expected results, and an overview of the projected fabrication, calibration, and launch timeline

New genetic loci link adipose and insulin biology to body fat distribution.

Body fat distribution is a heritable trait and a well-established predictor of adverse metabolic outcomes, independent of overall adiposity. To increase our understanding of the genetic basis of body fat distribution and its molecular links to cardiometabolic traits, here we conduct genome-wide association meta-analyses of traits related to waist and hip circumferences in up to 224,459 individuals. We identify 49 loci (33 new) associated with waist-to-hip ratio adjusted for body mass index (BMI), and an additional 19 loci newly associated with related waist and hip circumference measures (P < 5 × 10(-8)). In total, 20 of the 49 waist-to-hip ratio adjusted for BMI loci show significant sexual dimorphism, 19 of which display a stronger effect in women. The identified loci were enriched for genes expressed in adipose tissue and for putative regulatory elements in adipocytes. Pathway analyses implicated adipogenesis, angiogenesis, transcriptional regulation and insulin resistance as processes affecting fat distribution, providing insight into potential pathophysiological mechanisms

Technical Design Report for the: PANDA Micro Vertex Detector

This document illustrates the technical layout and the expected performance of the Micro Vertex Detector (MVD) of the PANDA experiment. The MVD will detect charged particles as close as possible to the interaction zone. Design criteria and the optimisation process as well as the technical solutions chosen are discussed and the results of this process are subjected to extensive Monte Carlo physics studies. The route towards realisation of the detector is outlined.Comment: 189 pages, 225 figures, 41 table

Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes.

OBJECTIVE: Proinsulin is a precursor of mature insulin and C-peptide. Higher circulating proinsulin levels are associated with impaired β-cell function, raised glucose levels, insulin resistance, and type 2 diabetes (T2D). Studies of the insulin processing pathway could provide new insights about T2D pathophysiology. RESEARCH DESIGN AND METHODS: We have conducted a meta-analysis of genome-wide association tests of ∼2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) and fasting proinsulin levels in 10,701 nondiabetic adults of European ancestry, with follow-up of 23 loci in up to 16,378 individuals, using additive genetic models adjusted for age, sex, fasting insulin, and study-specific covariates. RESULTS: Nine SNPs at eight loci were associated with proinsulin levels (P < 5 × 10(-8)). Two loci (LARP6 and SGSM2) have not been previously related to metabolic traits, one (MADD) has been associated with fasting glucose, one (PCSK1) has been implicated in obesity, and four (TCF7L2, SLC30A8, VPS13C/C2CD4A/B, and ARAP1, formerly CENTD2) increase T2D risk. The proinsulin-raising allele of ARAP1 was associated with a lower fasting glucose (P = 1.7 × 10(-4)), improved β-cell function (P = 1.1 × 10(-5)), and lower risk of T2D (odds ratio 0.88; P = 7.8 × 10(-6)). Notably, PCSK1 encodes the protein prohormone convertase 1/3, the first enzyme in the insulin processing pathway. A genotype score composed of the nine proinsulin-raising alleles was not associated with coronary disease in two large case-control datasets. CONCLUSIONS: We have identified nine genetic variants associated with fasting proinsulin. Our findings illuminate the biology underlying glucose homeostasis and T2D development in humans and argue against a direct role of proinsulin in coronary artery disease pathogenesis

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

The Colorado Ultraviolet Transit Experiment (CUTE): a dedicated cubesat mission for the study of exoplanetary mass loss and magnetic fields

The Colorado Ultraviolet Transit Experiment (CUTE) is a near-UV (2550 to 3300 angstrom) 6U CubeSat mission designed to monitor transiting hot Jupiters to quantify their atmospheric mass loss and magnetic fields. CUTE will probe both atomic (Mg and Fe) and molecular (OH) lines for evidence of enhanced transit absorption, and to search for evidence of early ingress due to bow shocks ahead of the planet's orbital motion. As a dedicated mission, CUTE will observe greater than or similar to 100 spectroscopic transits of hot Jupiters over a nominal 7-month mission. This represents the equivalent of >700 orbits of the only other instrument capable of these measurements, the Hubble Space Telescope. CUTE efficiently utilizes the available CubeSat volume by means of an innovative optical design to achieve a projected effective area of similar to 28 cm(2), low instrumental background, and a spectral resolving power of R similar to 3000 over the primary science bandpass. These performance characteristics enable CUTE to discern transit depths between 0.1% and 1% in individual spectral absorption lines. We present the CUTE optical and mechanical design, a summary of the science motivation and expected results, and an overview of the projected fabrication, calibration, and launch timeline. (c) 2018 Society of Photo-Optical Instrumentation Engineers (SPIE)National Aeronautics and Space Administration (NASA) [NNX17AI84G]No embargo.This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Colorado Ultraviolet Transit Experiment: a dedicated CubeSat mission to study exoplanetary mass loss and magnetic fields

The Colorado Ultraviolet Transit Experiment (CUTE) is a near-UV (2550 to 3300 angstrom) 6U CubeSat mission designed to monitor transiting hot Jupiters to quantify their atmospheric mass loss and magnetic fields. CUTE will probe both atomic (Mg and Fe) and molecular (OH) lines for evidence of enhanced transit absorption, and to search for evidence of early ingress due to bow shocks ahead of the planet's orbital motion. As a dedicated mission, CUTE will observe greater than or similar to 100 spectroscopic transits of hot Jupiters over a nominal 7-month mission. This represents the equivalent of >700 orbits of the only other instrument capable of these measurements, the Hubble Space Telescope. CUTE efficiently utilizes the available CubeSat volume by means of an innovative optical design to achieve a projected effective area of similar to 28 cm(2), low instrumental background, and a spectral resolving power of R similar to 3000 over the primary science bandpass. These performance characteristics enable CUTE to discern transit depths between 0.1% and 1% in individual spectral absorption lines. We present the CUTE optical and mechanical design, a summary of the science motivation and expected results, and an overview of the projected fabrication, calibration, and launch timeline. (c) 2018 Society of Photo-Optical Instrumentation Engineers (SPIE)National Aeronautics and Space Administration (NASA) [NNX17AI84G]No embargo.This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]